CA2544532C - Compositions comprising polypeptides - Google Patents
Compositions comprising polypeptides Download PDFInfo
- Publication number
- CA2544532C CA2544532C CA2544532A CA2544532A CA2544532C CA 2544532 C CA2544532 C CA 2544532C CA 2544532 A CA2544532 A CA 2544532A CA 2544532 A CA2544532 A CA 2544532A CA 2544532 C CA2544532 C CA 2544532C
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- multimeric
- antigen
- chromatographic material
- antigen binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03027511 | 2003-11-28 | ||
| EP03027511.9 | 2003-11-28 | ||
| PCT/EP2004/013445 WO2005052004A2 (en) | 2003-11-28 | 2004-11-26 | Compositions comprising polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2544532A1 CA2544532A1 (en) | 2005-06-09 |
| CA2544532C true CA2544532C (en) | 2015-06-16 |
Family
ID=34626385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2544532A Expired - Lifetime CA2544532C (en) | 2003-11-28 | 2004-11-26 | Compositions comprising polypeptides |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10000574B2 (enExample) |
| EP (2) | EP1691833B1 (enExample) |
| AT (1) | ATE459374T1 (enExample) |
| AU (1) | AU2004293182B2 (enExample) |
| BE (1) | BE2016C023I2 (enExample) |
| CA (1) | CA2544532C (enExample) |
| CY (2) | CY1110689T1 (enExample) |
| DE (1) | DE602004025840D1 (enExample) |
| DK (1) | DK1691833T3 (enExample) |
| ES (1) | ES2341252T3 (enExample) |
| FR (1) | FR16C1000I2 (enExample) |
| HU (1) | HUS1600019I1 (enExample) |
| LU (1) | LU93067I2 (enExample) |
| NL (1) | NL300807I2 (enExample) |
| PL (1) | PL1691833T3 (enExample) |
| PT (1) | PT1691833E (enExample) |
| SI (1) | SI1691833T1 (enExample) |
| WO (1) | WO2005052004A2 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5825756B2 (ja) | 2006-08-14 | 2015-12-02 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ１９を標的とする最適化抗体 |
| AU2007294575B2 (en) | 2006-09-08 | 2013-06-27 | Viela Bio, Inc. | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| EP2225275A4 (en) * | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
| US8658765B2 (en) | 2009-12-31 | 2014-02-25 | Avidbiotics Corp. | Non-natural MIC proteins |
| US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
| ES2787044T3 (es) | 2010-10-27 | 2020-10-14 | Amgen Res Munich Gmbh | Métodos para tratar LDCBG |
| US9402916B2 (en) | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| RU2632647C2 (ru) | 2011-04-22 | 2017-10-06 | Аптево Рисерч Энд Девелопмент Ллс | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| MX2016007885A (es) | 2013-12-17 | 2017-01-11 | Genentech Inc | Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20. |
| NZ760065A (en) | 2013-12-17 | 2022-12-23 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| TWI742423B (zh) | 2014-05-29 | 2021-10-11 | 美商宏觀基因股份有限公司 | 特異性結合多種癌症抗原的三特異性結合分子和其使用方法 |
| AU2015342964B2 (en) | 2014-11-05 | 2021-06-24 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
| CA2966558C (en) | 2014-11-05 | 2024-03-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
| EP3253419A1 (en) | 2015-02-02 | 2017-12-13 | The University of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
| MX388405B (es) | 2015-05-29 | 2025-03-19 | Genentech Inc | Un anticuerpo anti-pd-l1 para usarse en el tratamiento de cáncer en sujetos que tienen nivel medio o bajo de metilación en la región promotora pd-l1. |
| IL256080B2 (en) | 2015-06-17 | 2025-06-01 | Genentech Inc | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
| MX2018003292A (es) | 2015-09-21 | 2018-08-01 | Aptevo Res & Development Llc | Polipéptidos de unión a cd3. |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| PT3377103T (pt) | 2015-11-19 | 2021-05-26 | Revitope Ltd | Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas |
| ES2901794T3 (es) | 2015-12-09 | 2022-03-23 | Hoffmann La Roche | Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco |
| EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| AR107303A1 (es) | 2016-01-08 | 2018-04-18 | Hoffmann La Roche | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit |
| CA3059010A1 (en) | 2016-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| EP3494139B1 (en) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| CN109476748B (zh) | 2016-08-08 | 2023-05-23 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
| IL267284B2 (en) | 2016-12-19 | 2023-03-01 | Hoffmann La Roche | Combination therapy with a targeted 4-bb1 agonist (cd137) |
| KR102692708B1 (ko) | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법 |
| CN111315781A (zh) | 2017-11-01 | 2020-06-19 | 豪夫迈·罗氏有限公司 | 用靶向性ox40激动剂的组合疗法 |
| IL277174B2 (en) | 2018-03-13 | 2025-12-01 | Hoffmann La Roche | Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| CA3102562A1 (en) * | 2018-06-07 | 2019-12-12 | Cullinan Management, Inc. | Multi-specific binding proteins and methods of use thereof |
| MX2021003213A (es) | 2018-09-21 | 2021-05-12 | Genentech Inc | Metodos de diagnostico para cancer de mama triple negativo. |
| EP3877407B1 (en) | 2018-11-05 | 2026-03-11 | F. Hoffmann-La Roche AG | Methods of producing two chain proteins in prokaryotic host cells |
| WO2020221792A1 (en) | 2019-04-30 | 2020-11-05 | Amgen Research (Munich) Gmbh | Means and methods of treating burkitt lymphoma or leukemia |
| IL288024B2 (en) | 2019-05-14 | 2025-12-01 | Provention Bio Inc | Methods and compositions for preventing type |
| TWI905099B (zh) | 2019-05-21 | 2025-11-21 | 瑞士商諾華公司 | Cd19 結合分子及其用途 |
| WO2021119551A1 (en) | 2019-12-11 | 2021-06-17 | Cullinan Oncology, Inc. | Anti-cd19 antibodies and multi-specific binding proteins |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CA3181820A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
| KR102453073B1 (ko) * | 2020-08-14 | 2022-10-11 | 건국대학교 글로컬산학협력단 | 피키아 파스토리스를 이용한 이중특이적 항체의 제조방법 및 이에 따른 이중특이적 항체 |
| AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| CA3215049A1 (en) | 2021-04-10 | 2022-10-13 | Baiteng ZHAO | Folr1 binding agents, conjugates thereof and methods of using the same |
| WO2022226317A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| EP4329800A1 (en) | 2021-04-30 | 2024-03-06 | F. Hoffmann-La Roche AG | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| AU2021443318A1 (en) | 2021-04-30 | 2023-09-07 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| EP4083061A1 (en) * | 2021-04-30 | 2022-11-02 | Kilometro Rosso SPA | Fusion proteins and use thereof in the treatment of membranous nephropathy |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| MX2024011468A (es) | 2022-03-23 | 2024-09-25 | Hoffmann La Roche | Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia. |
| AU2023251832A1 (en) | 2022-04-13 | 2024-10-17 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
| WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
| CN120152989A (zh) | 2022-11-03 | 2025-06-13 | 豪夫迈·罗氏有限公司 | 抗cd19/抗cd28双特异性抗体的组合疗法 |
| AU2024275646A1 (en) | 2023-05-24 | 2025-11-13 | Mozart Therapeutics, Inc. | Cd8-specific binding proteins and methods of using the same |
| WO2024261013A1 (en) | 2023-06-21 | 2024-12-26 | F. Hoffmann-La Roche Ag | Combination therapy with fap-targeted lymphotoxin beta receptor agonists |
| AR133955A1 (es) | 2023-09-26 | 2025-11-19 | Profoundbio Us Co | Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
| TW202547866A (zh) | 2024-01-10 | 2025-12-16 | 丹麥商珍美寶股份有限公司 | Ｓｌｉｔｒｋ６結合劑、其共軛物及使用彼之方法 |
| US20250381289A1 (en) | 2024-02-29 | 2025-12-18 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2025222129A2 (en) | 2024-04-19 | 2025-10-23 | Mozart Therapeutics, Inc. | Engineered cytokines and targeted cytokine delivery |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| DK0573551T3 (da) | 1991-02-27 | 2003-08-04 | Micromet Ag | Serinrige peptidlinkere |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| DK1071752T3 (da) * | 1998-04-21 | 2003-10-20 | Micromet Ag | CD19xCD3-specifikke polypeptider og anvendelsen deraf |
| US20020142964A1 (en) * | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
-
2004
- 2004-11-26 PL PL04803302T patent/PL1691833T3/pl unknown
- 2004-11-26 AU AU2004293182A patent/AU2004293182B2/en not_active Expired
- 2004-11-26 PT PT04803302T patent/PT1691833E/pt unknown
- 2004-11-26 DK DK04803302.1T patent/DK1691833T3/da active
- 2004-11-26 EP EP04803302A patent/EP1691833B1/en not_active Expired - Lifetime
- 2004-11-26 SI SI200431360T patent/SI1691833T1/sl unknown
- 2004-11-26 CA CA2544532A patent/CA2544532C/en not_active Expired - Lifetime
- 2004-11-26 US US10/580,660 patent/US10000574B2/en active Active
- 2004-11-26 ES ES04803302T patent/ES2341252T3/es not_active Expired - Lifetime
- 2004-11-26 DE DE602004025840T patent/DE602004025840D1/de not_active Expired - Lifetime
- 2004-11-26 AT AT04803302T patent/ATE459374T1/de active
- 2004-11-26 EP EP10155222A patent/EP2186527A1/en not_active Withdrawn
- 2004-11-26 WO PCT/EP2004/013445 patent/WO2005052004A2/en not_active Ceased
-
2010
- 2010-05-27 CY CY20101100465T patent/CY1110689T1/el unknown
-
2016
- 2016-05-03 NL NL300807C patent/NL300807I2/nl unknown
- 2016-05-05 CY CY2016010C patent/CY2016010I1/el unknown
- 2016-05-05 HU HUS1600019C patent/HUS1600019I1/hu unknown
- 2016-05-10 BE BE2016C023C patent/BE2016C023I2/fr unknown
- 2016-05-11 LU LU93067C patent/LU93067I2/fr unknown
- 2016-05-20 FR FR16C1000C patent/FR16C1000I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004025840D1 (de) | 2010-04-15 |
| US20070249529A1 (en) | 2007-10-25 |
| WO2005052004A2 (en) | 2005-06-09 |
| CY1110689T1 (el) | 2015-06-10 |
| AU2004293182B2 (en) | 2010-02-18 |
| DK1691833T3 (da) | 2010-05-03 |
| CA2544532A1 (en) | 2005-06-09 |
| EP1691833B1 (en) | 2010-03-03 |
| ES2341252T3 (es) | 2010-06-17 |
| WO2005052004A3 (en) | 2006-03-09 |
| ATE459374T1 (de) | 2010-03-15 |
| HUS1600019I1 (hu) | 2016-06-28 |
| AU2004293182A1 (en) | 2005-06-09 |
| FR16C1000I1 (enExample) | 2016-06-24 |
| PT1691833E (pt) | 2010-06-08 |
| LU93067I2 (fr) | 2016-07-11 |
| US10000574B2 (en) | 2018-06-19 |
| CY2016010I2 (el) | 2016-08-31 |
| SI1691833T1 (sl) | 2010-06-30 |
| EP2186527A1 (en) | 2010-05-19 |
| FR16C1000I2 (fr) | 2017-02-03 |
| PL1691833T3 (pl) | 2010-08-31 |
| BE2016C023I2 (enExample) | 2023-12-18 |
| EP1691833A2 (en) | 2006-08-23 |
| CY2016010I1 (el) | 2016-08-31 |
| NL300807I2 (enExample) | 2016-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2544532C (en) | Compositions comprising polypeptides | |
| JP7262597B2 (ja) | 二重特異性抗体及びその作製方法と使用 | |
| AU2016336866B2 (en) | Multivalent Fv antibodies | |
| RU2753882C2 (ru) | Трифункциональная антигенсвязывающая молекула | |
| EP4582449A1 (en) | Recombinant humanized monoclonal antibody targeting human gprc5d and application thereof | |
| Morris et al. | Development and characterization of recombinant human Fc: OX40L fusion protein linked via a coiled-coil trimerization domain | |
| KR20170041697A (ko) | 이중특이적 cd33 및 cd3 결합 단백질 | |
| CA2924252A1 (en) | Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions | |
| RS61590B1 (sr) | Monoklonsko antitelo protiv ctla4 ili njegov antigen-vezujući fragment, medicinska kompozicija i upotreba | |
| ZA200506282B (en) | Trimeric polypeptide construct to induce an enduring T cell response | |
| KR20180014066A (ko) | 이중특이적 cd33 및 cd3 결합 단백질을 사용하는 방법 | |
| CN116635071A (zh) | 抗tspan8-抗cd3双特异性抗体和抗tspan8抗体 | |
| JP2024514246A (ja) | Ｃｌｄｎ１８．２抗原結合タンパク質およびその使用 | |
| CN108840932A (zh) | 一种pd-1特异性抗体及其抗肿瘤应用 | |
| JP2025539875A (ja) | 融合ポリペプチドおよびその使用 | |
| CN109422814A (zh) | 一种抗La/SSB嵌合体抗原修饰的NK细胞、其制备方法及其应用 | |
| CN110872356B (zh) | 双特异性抗体及其使用方法 | |
| CN111484554B (zh) | 一种靶向4-1bb的肿瘤抑制性抗体及其应用 | |
| RU2785766C2 (ru) | Мультивалентные fv-антитела | |
| RU2785766C9 (ru) | Мультивалентные fv-антитела | |
| CN120775047A (zh) | 靶向Claudin18.2的抗体及其应用 | |
| HK40118946A (zh) | 作为pd-1激动剂的程序性细胞死亡蛋白1的抗体 | |
| NZ745376B2 (en) | Method and compositions for cellular immunotherapy | |
| NZ745374B2 (en) | Method and compositions for cellular immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |